In lung cancer, EGFR mutations are associated with increased PD-L1 activation, promoting immune evasion and creating an immunosuppressive tumor microenvironment (TME) by recruiting tumor-associated macrophages (TAMs) and regulatory T cells (Tregs) [18]. The gene discussed is CD274; the disease is neoplasm.